FDA approves first drug therapy for Alzheimer's in 18 years

FDA approves first drug therapy for Alzheimer's in 18 years

The Food and Drug Administration (FDA) last week approved Aduhelm (aducanumab), considered the first novel therapy to be approved for Alzheimer's patients since 2003. The timely and long‐awaited June 8 announcement arrives during National Alzheimer's & Brain Awareness Month.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mental Health Weekly 2021-06, Vol.31 (23), p.3-4
1. Verfasser: Canady, Valerie A.
Format: Artikel
Sprache:eng
Schlagworte:
Alzheimer's disease
Drug approval
Drug therapy
FDA approval
Mental health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Food and Drug Administration (FDA) last week approved Aduhelm (aducanumab), considered the first novel therapy to be approved for Alzheimer's patients since 2003. The timely and long‐awaited June 8 announcement arrives during National Alzheimer's & Brain Awareness Month.
ISSN:1058-1103
1556-7583
DOI:10.1002/mhw.32827